ChemicalBook >제품 카탈로그 >제약 중간체>벌크 의약품 중간체>Vonoprazan fumarate

Vonoprazan fumarate

Vonoprazan fumarate 구조식 이미지

카스 번호:: 1260141-27-2

상품명:: Vonoprazan fumarate

동의어(영문):: Vonoprazan FuMarate;Vonaprazan;5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate (Vonoprazan);Vonaprazan(TAK-438);Vonoprazon Fumarate;Vonoprazan fumarate(TAK-438);vonoprazan(tak-438)1260141-27-2;5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine,(E)-4-oxopent-2-enoic acid;AK-438

CBNumber:: CB32628441

분자식:: C21H20FN3O6S

포뮬러 무게:: 461.4634032

MOL 파일:: 1260141-27-2.mol

속성

안전

용도

공급 업체 472

Vonoprazan fumarate 속성

저장 조건: Store at -20°C

용해도: insoluble in H2O; insoluble in EtOH; ≥18.9 mg/mL in DMSO

물리적 상태: 고체

물리적 상태: 단단한 모양

InChIKey: ROGSHYHKHPCCJW-WLHGVMLRSA-N

SMILES: N1(S(C2=CC=CN=C2)(=O)=O)C(C2=CC=CC=C2F)=CC(CNC)=C1.C(O)(=O)/C=C/C(O)=O

안전

위험 및 안전 성명
위험 및 사전주의 사항 (GHS)

그림문자(GHS):

신호 어:

Warning

유해·위험 문구:

암호	유해·위험 문구	위험 등급	범주	신호 어	P- 코드
H315	피부에 자극을 일으킴	피부부식성 또는 자극성물질	구분 2	경고	P264, P280, P302+P352, P321,P332+P313, P362
H319	눈에 심한 자극을 일으킴	심한 눈 손상 또는 자극성 물질	구분 2A	경고	P264, P280, P305+P351+P338,P337+P313P
H335	호흡 자극성을 일으킬 수 있음	특정 표적장기 독성 - 1회 노출;호흡기계 자극	구분 3	경고

예방조치문구:

P261	분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P264	취급 후에는 손을 철저히 씻으시오.
P264	취급 후에는 손을 철저히 씻으시오.
P271	옥외 또는 환기가 잘 되는 곳에서만 취급하시오.
P280	보호장갑/보호의/보안경/안면보호구를 착용하시오.
P302+P352	피부에 묻으면 다량의 물로 씻으시오.
P304+P340	흡입하면 신선한 공기가 있는 곳으로 옮기고 호흡하기 쉬운 자세로 안정을 취하시오.
P305+P351+P338	눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
P312	불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.
P321	(…) 처치를 하시오.
P332+P313	피부 자극이 생기면 의학적인 조치· 조언을 구하시오.
P337+P313	눈에 대한 자극이 지속되면 의학적인 조치· 조언를 구하시오.
P403+P233	용기는 환기가 잘 되는 곳에 단단히 밀폐하여 저장하시오.
P405	밀봉하여 저장하시오.
P501	...에 내용물 / 용기를 폐기 하시오.

NFPA 704

	0
2		0

Vonoprazan fumarate C화학적 특성, 용도, 생산

개요

Vonoprazan fumarate (Takecab®), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has a novel mechanism of action called potassium-competitive acid blockers, which competitively inhibit the binding of potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan does not inhibit Na+, K+-ATPase activity even at concentrations 500 times higher than that of their IC50 values against gastric H+, K+-ATPase activity. Furthermore, the drug is unaffected by the gastric secretory state, unlike PPIs.

용도

Vonoprazan Fumarate is a novel potassium-?competitive acid blocker for the treatment of acid-?related diseases.

주요 응용

Vonoprazan fumarate is an oral, newly synthesised potassium-competitive acid blocker (P-CAB) with antisecretory activity. It is also a proton pump inhibitor (PPI) reversibly inhibiting H+/K+, ATPase. It is mainly used in the treatment of acid-related diseases such as GERD and peptic ulcer disease.

Synthesis

Commercially available 2-fluoroacetophenone (283) was brominated to yield a-bromo-acetophenone derivative 284. This compound was treated with ethyl 2-cyanoacetate (285) under basic conditions to provide ketoester 286 in essentially quantitative yield. Next, intramolecular condensation of 286 upon treatment of 4 M HCl furnished the tri-substituted pyrrole 287 in 53% yield. Reduction of the chloride under hydrogenolytic conditions facilitated arrival at pyrrole 288, albeit in just 18% yield. Subsequent diisobutylaluminium hydride (DIBAL) reduction, followed by the oxidation with tetrapropylammonium perruthenate (TPAP) and 4-methylmorpholine N-oxide (NMMO) afforded the corresponding aldehyde 290 in 60% yield across the 2 steps. Next, N-pyrrole substitution with pyridine- 3-sulfonyl chloride 291 gave rise to N-sulfonylpyrrole 292 in 82% yield. Reductive amination of 292 afforded amine 293, which was treated with fumaric acid (294) via co-crystallization to provide vonoprazan fumarate (XXXVI) in 74% for the two steps.

Synthesis_1260141-27-2

Vonoprazan fumarate 준비 용품 및 원자재

원자재

준비 용품

Vonoprazan fumarate 공급 업체

글로벌( 472)공급 업체

공급자	전화	이메일	국가	제품 수	이점
Beijing Mesochem Technology Co.,Ltd	+8613651027935	rachel@mesochem.com	China	191	58
TAIZHOU YUXIN BIOTECHNOLOGY CO,.LTD	+86-576-88902229;+86-0576-88902229 +8613968687450	yuxin@yuxchem.com	China	158	58
Hangzhou ICH Biofarm Co., Ltd	+86-0571-28186870; +undefined8613073685410	sales@ichemie.com	China	985	58
Beijing Hope Pharmaceutical Co., Ltd.	+86-010-67886402 +8613611125266	market@hopelife.cn	China	71	58
Hebei Mojin Biotechnology Co., Ltd	+8613288715578	sales@hbmojin.com	China	12470	58
XI'AN TIANGUANGYUAN BIOTECH CO., LTD.	+86-029-86333380 18829239519	sales06@tgybio.com	China	935	58
Changzhou Rokechem Technology Co., Ltd.	18758118018	sales001@rokechem.com	China	255	58
Firsky International Trade (Wuhan) Co., Ltd	+8615387054039	admin@firsky-cn.com	China	436	58
shandong perfect biotechnology co.ltd	+86-53169958659; +8618596095638	sales@sdperfect.com	China	294	58
Zibo Hangyu Biotechnology Development Co., Ltd	+86-0533-2185556 +8617865335152	Mandy@hangyubiotech.com	China	11013	58

Vonoprazan fumarate 관련 검색:

에소메프라졸 Vonoprazan Vonoprazan FuMarate Donepezil Hydrochloride ETOFIBRATE Fosaprepitant dimeglumine Lansoprazole Pantoprazole 2-PYRIMIDINAMINE, 4-(3,4-DIHYDRO-1-METHYL-2(1H)-ISOQUINOLINYL)-N-(4-FLUOROPHENYL)-5,6-DIMETHYL-, MONOHYDROCHLORIDE R-(+)-Lansoprazole Teneligliptin Hydrobromide Trelagliptin succinate Trelagliptin Alogliptin benzoate Linagliptin AGOMELATINE ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) 5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbaldehyde